Elie A. Akl
Statistics and Probability · 2009–2024
A researcher in the Science corpus: 30 papers; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Statistics and Probability — 272 citations into it
- General Health Professions — 127 citations into it
- Economics and Econometrics — 114 citations into it
- Public Health, Environmental and Occupational Health — 98 citations into it
Whom Elie A. Akl trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Elie A. Akl overall
Papers from Elie A. Akl's perspective
Ordered by how strongly the researchers Elie A. Akl trusts endorse each paper. Same corpus, a different order for every researcher.
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
- GRADE guidelines: 2. Framing the question and deciding on important outcomes. (Journal of Clinical Epidemiology)
- Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. (Blood)
- Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications (British medical journal)
- A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. (New England Journal of Medicine)
- When are randomised trials unnecessary? Picking signal from noise (British medical journal)
- Selective publication of antidepressant trials and its influence on apparent efficacy. (New England Journal of Medicine)
- The safety of statins in clinical practice. (The Lancet)
- External validity of randomised controlled trials: "to whom do the results of this trial apply?".
- Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study (British medical journal)
Their papers
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (2011) — 9,069 citations
- GRADE guidelines: 5. Rating the quality of evidence--publication bias. (2011) — 1,582 citations
- GRADE guidelines: 8. Rating the quality of evidence--indirectness. (2011) — 1,166 citations
- GRADE guidelines: 7. Rating the quality of evidence--inconsistency. (2011) — 1,457 citations
- GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). (2011) — 2,570 citations
- PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews (2020) — 10,812 citations
- PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation (2018) — 31,635 citations
- GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. (2013) — 683 citations
- The GRADE Working Group clarifies the construct of certainty of evidence (2017) — 611 citations
- Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. (2010) — 602 citations
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2020) — 94,440 citations
- GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. (2013) — 1,344 citations
- GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. (2013) — 641 citations
- The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. (2021) — 3,176 citations
- Grading quality of evidence and strength of recommendations in clinical practice guidelines (2009) — 818 citations
- GRADE guidelines: 9. Rating up the quality of evidence. (2011) — 1,187 citations
- GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. (2017) — 550 citations
- GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction (2016) — 732 citations
- A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E) (2024) — 789 citations
- The PRISMA 2020 statement: An updated guideline for reporting systematic reviews (2021) — 25,061 citations